Press & Publications

Meet us

European College of Neuropsychopharmacology (ECNP) Conference

From 11th to 14th October 2025 in Amsterdam

Join us on October 14th for the presentation of our latest research during Poster Session 4, at 12:35 pm CET. Our work titled “RNA editing signatures powered by artificial intelligence: a new frontier in differentiating schizophrenia, bipolar and schizoaffective disorders” (poster PS04-3308) will be presented by our CSO, Dr. Dinah Weissmann. Joining her will be our Deputy Scientific Director Dr. Francisco Santos Schneider.

Looking forward to discussing the latest advancements in Precision medicine, Artificial Intelligence and computational models, and Biomarkers!

Press

https://www.alcediag-alcen.com/wp-content/uploads/2023/03/SynLab-logo.svg
Press Release | March 27, 2023

ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/Ouest-France-image.jpeg
News | November 18, 2022

OUEST-FRANCE À Montpellier, une start-up développe un test pour diagnostiquer la bipolarité

https://www.alcediag-alcen.com/wp-content/uploads/2024/01/ALCEDIAG-1.png
News | July 12, 2022

ALCEDIAG Announces the Inclusion of the First Patient in clinical validation study for EDIT-B test: an aid for differential diagnosis of bipolar disorder, based on RNA editing blood biomarkers

Scientific Publications

Translational Psychiatry | August 20, 2016

In vitro screening for drug-induced depression and/or suicidal adverse effects: a new toxicogenomic assay based on CE-SSCP analysis of HTR2C mRNA editing in SH-SY5Y cells

D Weissmann, S van der Laan, MD Underwood, N Salvetat, L Cavarec, L Vincent, F Molina, JJ Mann, V Arango and JF Pujol